File Download

There are no files associated with this item.

Conference Paper: To compare the efficacy and safety of argon laser peripheral iridoplasty (ALPI) to systemic intraocular pressure (IOP) lowering medications in the immediate management of acute phacomorphic angle closure

TitleTo compare the efficacy and safety of argon laser peripheral iridoplasty (ALPI) to systemic intraocular pressure (IOP) lowering medications in the immediate management of acute phacomorphic angle closure
Authors
Issue Date2012
Citation
The 8th International Symposium of Ophthalmology - Hong Kong (ISOHK 2012), Hong Kong, China, 14-16 December 2012 How to Cite?
AbstractBACKGROUND: The purpose of this study was to compare the efficacy and safety of argon laser peripheral iridoplasty (ALPI) and systemic intraocular pressure (IOP)-lowering medications in the immediate management of acute phacomorphic angle closure. METHODS: Consecutive cases of acute phacomorphic angle closure were randomized to receive ALPI and an intravenous or oral carbonic anhydrase inhibitor as initial treatment. Intravenous mannitol was administered for presenting IOP > 60 mmHg or IOP > 40 mmHg 2 hours posttreatment in both arms. RESULTS: Of 10 consecutive cases, six received medical therapy and four received ALPI. Fifty percent in the medical group and none in the ALPI group required intravenous mannitol. The ALPI group took less time to achieve IOP < 25 mmHg (18.8 ± 7.5 minutes versus 115.0 ± 97.0 minutes, P = 0.001, F test); had a greater IOP reduction within 30 minutes (69.8% ± 7.7% versus 40.9 ± 23.9%, P = 0.03, t-test); and had a consistently smaller post-attack cup to disc ratio (0.50 ± 0.02 versus 0.60 ± 0.20, P = 0.002, F test). CONCLUSION: ALPI offers greater safety, consistency, and efficacy than systemic IOP-lowering medications as initial treatment for phacomorphic angle closure.
DescriptionGlaucoma free paper session 3
Persistent Identifierhttp://hdl.handle.net/10722/208663

 

DC FieldValueLanguage
dc.contributor.authorLee, WYJ-
dc.contributor.authorLai, JSM-
dc.contributor.authorYick, DW-
dc.contributor.authorYuen, CY-
dc.date.accessioned2015-03-18T06:36:59Z-
dc.date.available2015-03-18T06:36:59Z-
dc.date.issued2012-
dc.identifier.citationThe 8th International Symposium of Ophthalmology - Hong Kong (ISOHK 2012), Hong Kong, China, 14-16 December 2012-
dc.identifier.urihttp://hdl.handle.net/10722/208663-
dc.descriptionGlaucoma free paper session 3-
dc.description.abstractBACKGROUND: The purpose of this study was to compare the efficacy and safety of argon laser peripheral iridoplasty (ALPI) and systemic intraocular pressure (IOP)-lowering medications in the immediate management of acute phacomorphic angle closure. METHODS: Consecutive cases of acute phacomorphic angle closure were randomized to receive ALPI and an intravenous or oral carbonic anhydrase inhibitor as initial treatment. Intravenous mannitol was administered for presenting IOP > 60 mmHg or IOP > 40 mmHg 2 hours posttreatment in both arms. RESULTS: Of 10 consecutive cases, six received medical therapy and four received ALPI. Fifty percent in the medical group and none in the ALPI group required intravenous mannitol. The ALPI group took less time to achieve IOP < 25 mmHg (18.8 ± 7.5 minutes versus 115.0 ± 97.0 minutes, P = 0.001, F test); had a greater IOP reduction within 30 minutes (69.8% ± 7.7% versus 40.9 ± 23.9%, P = 0.03, t-test); and had a consistently smaller post-attack cup to disc ratio (0.50 ± 0.02 versus 0.60 ± 0.20, P = 0.002, F test). CONCLUSION: ALPI offers greater safety, consistency, and efficacy than systemic IOP-lowering medications as initial treatment for phacomorphic angle closure.-
dc.languageeng-
dc.relation.ispartofInternational Symposium of Ophthalmology - Hong Kong, ISOHK 2012-
dc.titleTo compare the efficacy and safety of argon laser peripheral iridoplasty (ALPI) to systemic intraocular pressure (IOP) lowering medications in the immediate management of acute phacomorphic angle closure-
dc.typeConference_Paper-
dc.identifier.emailLee, WYJ: jackylee@hku.hk-
dc.identifier.emailLai, JSM: laism@hku.hk-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats